Human Immunodeficiency Virus

13
Pipeline Programs
7
Companies
19
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
3
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 20 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
8 programs
3
3
BIKTARVY 50Mg-200Mg-25Mg TabletPhase 41 trial
Single Dose ElivitegravirPhase 4Small Molecule1 trial
bictegravir/emtricitabine/tenofovir alafenamidePhase 41 trial
BiktarvyPhase 32 trials
E/C/F/TAF;Phase 31 trial
+3 more programs
Active Trials
NCT04560556Completed122Est. Nov 2021
NCT04653194Completed36Est. Jul 2023
NCT04519970Completed100Est. Apr 2024
+4 more trials
M&
Merck & Co.RAHWAY, NJ
5 programs
2
2
EBR/GZRPhase 41 trial
emtricitabine/tenofovir disoproxil fumaratePhase 41 trial
MK-8527Phase 11 trial
MK-8527Phase 11 trial
RaltegravirN/ASmall Molecule1 trial
Active Trials
NCT02218320Completed20Est. Oct 2015
NCT03615183Completed17Est. Sep 2019
NCT05494736Completed20Est. Jan 2024
+2 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
3
CP-675,206Phase 21 trial
CapravirinePhase 21 trial
MaravirocPhase 21 trial
Active Trials
NCT00488995Withdrawn0
NCT00051844Completed179Est. Nov 2004
NCT00791700Unknown103Est. Jun 2023
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
Dolutegravir 50 MGN/A1 trial
Initiation of anti-retroviral therapyN/A1 trial
Active Trials
NCT03512964CompletedEst. Sep 2020
NCT01490346CompletedEst. Sep 2014
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
Kaletra in Combination With Antiretroviral AgentsN/A
Kaletra: Therapy With Double Protease InhibitorsN/A
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Integrated e-healthcare servicesN/A1 trial
Active Trials
NCT04179344CompletedEst. Oct 2019
Abbott
AbbottABBOTT PARK, IL
1 program
Kaletra in Combination With Antiretroviral AgentsN/A1 trial
Active Trials
NCT01076179Completed502Est. Jan 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesBIKTARVY 50Mg-200Mg-25Mg Tablet
Gilead Sciencesbictegravir/emtricitabine/tenofovir alafenamide
Merck & Co.EBR/GZR
Gilead SciencesSingle Dose Elivitegravir
Merck & Co.emtricitabine/tenofovir disoproxil fumarate
Gilead SciencesBiktarvy
Gilead SciencesE/C/F/TAF;
PfizerMaraviroc
PfizerCP-675,206
PfizerCapravirine
Merck & Co.MK-8527
Merck & Co.MK-8527
Gilead SciencesPoint-of-Care
Gilead SciencesBiktarvy
City TherapeuticsIntegrated e-healthcare services

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 1,347 patients across 19 trials

NCT04944654Gilead SciencesBIKTARVY 50Mg-200Mg-25Mg Tablet

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Start: Jan 2023Est. completion: May 20231 patients
Phase 4Terminated
NCT03502005Gilead Sciencesbictegravir/emtricitabine/tenofovir alafenamide

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Start: Mar 2018Est. completion: Dec 2019100 patients
Phase 4Completed

Impact of Hepatitis C Therapy and Bone Health

Start: Aug 2017Est. completion: Nov 20186 patients
Phase 4Terminated
NCT01855867Gilead SciencesSingle Dose Elivitegravir

HIV Non-Occupational Post-Exposure Prophylaxis

Start: May 2013Est. completion: Apr 2016100 patients
Phase 4Completed
NCT01234116Merck & Co.emtricitabine/tenofovir disoproxil fumarate

Post-Exposure Prophylaxis in Health Care Workers

Start: Feb 2011Est. completion: May 201316 patients
Phase 4Completed

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Start: Sep 2020Est. completion: Jul 202336 patients
Phase 3Completed

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

Start: Apr 2016Est. completion: Jun 201825 patients
Phase 3Completed

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Start: Apr 2009Est. completion: Jun 2023103 patients
Phase 2Unknown

Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

Start: Jul 20070
Phase 2Withdrawn

Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

Start: Aug 2002Est. completion: Nov 2004179 patients
Phase 2Completed

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Start: Nov 2022Est. completion: Jan 202420 patients
Phase 1Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Start: Feb 2019Est. completion: Sep 201917 patients
Phase 1Completed

Linking Persons With HIV, Discharged From Jail, With Community Care

Start: Nov 2020Est. completion: Nov 2021122 patients
N/ACompleted

Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)

Start: Sep 2020Est. completion: Apr 2024100 patients
N/ACompleted
NCT04179344City TherapeuticsIntegrated e-healthcare services

Usability Study of IeHS in Indonesia

Start: Aug 2019Est. completion: Oct 2019
N/ACompleted

Rapid HIV Treatment Initiation, Access and Engagement in Care

Start: Nov 2016Est. completion: Sep 2020
N/ACompleted

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

Start: Oct 2014Est. completion: Oct 201520 patients
N/ACompleted
NCT01076179AbbottKaletra in Combination With Antiretroviral Agents

Kaletra in Combination With Antiretroviral Agents

Start: Sep 2008Est. completion: Jan 2016502 patients
N/ACompleted
NCT01490346Allergy TherapeuticsInitiation of anti-retroviral therapy

Tissue Drug Levels of HIV Medications

Start: Sep 2008Est. completion: Sep 2014
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space